Local biotechs have been busy this spring raising funds through highly successful IPOs and funding rounds. Boston-based Talaris Therapeutics’ IPO, which closed on May 11, raised approximately $150 million for the company. Known as Regenerex at its founding in 2002, Talaris, is a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic […]

Cambridge-based iTeos Therapeutics and GlaxoSmithKline (GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical […]

Lexington biotech Agenus has granted Bristol Myers Squibb an exclusive global license for its proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies […]

The FDA has granted accelerated approval to Biogen and Eisai  for Aduhelm™ (aducanumab-avwa), a human monoclonal antibody, as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. Biogen licensed Aduhelm from Neurimmune in 2007 under a collaborative development and license agreement. […]

Moderna is expanding its Moderna Technology Center (MTC) in Norwood including more than doubling of space to transform the facility from a production and lab space to an industrial technology center. This expansion includes increasing the company’s production and lab space from approximately 300,000 square feet to approximately 650,000 square feet through renovation of existing […]